Publicaciones en colaboración con investigadores/as de Heidelberg University (18)

2011

  1. Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: Results of the AIEOP-BFM-ALL 2000 study

    Blood, Vol. 118, Núm. 8, pp. 2077-2084

2010

  1. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: A European MCL intergroup study

    Blood, Vol. 115, Núm. 16, pp. 3215-3223

  2. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: Results in 3184 patients of the AIEOP-BFMALL 2000 study

    Blood, Vol. 115, Núm. 16, pp. 3206-3214

2008

  1. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia

    Leukemia, Vol. 22, Núm. 4, pp. 771-782

  2. The 3D Structure of the Immunoglobulin Heavy-Chain Locus: Implications for Long-Range Genomic Interactions

    Cell, Vol. 133, Núm. 2, pp. 265-279

2007

  1. Analysis of minimal residual disease by Ig/TCR gene rearrangements: Guidelines for interpretation of real-time quantitative PCR data

    Leukemia

  2. Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting

    Leukemia, Vol. 21, Núm. 4, pp. 706-713

  3. Polymerase chain reaction-based clonality testing in tissue samples with reactive lymphoproliferations: Usefulness and pitfalls. A report of the BIOMED-2 Concerted Action BMH4-CT98-3936

    Leukemia, Vol. 21, Núm. 2, pp. 222-229

2006

  1. Aberrant methylation in promoter-associated CpG islands of multiple genes in acute lymphoblastic leukemia

    Leukemia Research, Vol. 30, Núm. 1, pp. 98-102

2004

  1. Aberrant methylation in promoter-associated CpG islands of multiple genes in relapsed childhood acute lymphoblastic leukemia

    Oncology Reports, Vol. 12, Núm. 1, pp. 97-99

  2. High incidence and unique features of antigen receptor gene rearrangements in TEL-AML1-positive leukemias

    Leukemia, Vol. 18, Núm. 1, pp. 84-91

2003

  1. Allelotype analysis in relapsed childhood acute lymphoblastic leukemia

    Oncogene, Vol. 22, Núm. 44, pp. 6970-6976

2002

  1. Detection of minimal residual disease identifies differences in treatment response between T-ALL and precursor B-ALL

    Blood, Vol. 99, Núm. 12, pp. 4386-4393

  2. Molecular monitoring of residual disease using antigen receptor genes in childhood acute lymphoblastic leukaemia

    Best Practice and Research: Clinical Haematology, Vol. 15, Núm. 1, pp. 37-57

2000

  1. Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the international BFM study group

    Leukemia, Vol. 14, Núm. 11, pp. 1939-1943

1999

  1. Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets. Report of the BIOMED-1 CONCERTED ACTION: Investigation of minimal residual disease in acute leukemia

    Leukemia, Vol. 13, Núm. 1, pp. 110-118

1998

  1. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood

    Lancet, Vol. 352, Núm. 9142, pp. 1731-1738

1983

  1. Case 31-1983: Richter's Syndrome

    New England Journal of Medicine